Enanta Pharmaceuticals, Inc
Symbol: ENTA (NASDAQ)
8.28
▼ (-4.45%) -0.385
Company Description:
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Key Stats
- Today's Open: $8.57
- Today's High: $8.815
- Today's Low: $8.256
- Today's Volume: 223.75K
- Yesterday Close: $8.66
- Yesterday High: $8.79
- Yesterday Low: $8.245
- Yesterday Volume: 208.06K
- Last Min Volume: 8
- Last Min High: $8.275
- Last Min Low: $8.275
- Last Min VWAP: $8.275
Company Profile
- Name: Enanta Pharmaceuticals, Inc
- Website: https://www.enanta.com
- Listed Date: 2013-03-21
- Location: WATERTOWN, MA
- Market Status: Active
- CIK Number: 0001177648
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $185.13M
- Round Lot: 100
- Outstanding Shares: 21.38M
- Asset Type: CS
RECENT FILINGS FOR ENTA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 3 | View |
| 2025-09-08 | 3 | View |
| 2025-08-27 | 8-K | View |
| 2025-08-20 | 8-K | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-08-08 | 4 | View |
| 2025-05-14 | S-8 | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-04-17 | SCHEDULE 13G/A | View |
| 2025-03-17 | 8-K | View |
| 2025-03-14 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-02-14 | SCHEDULE 13D/A | View |
| 2025-02-14 | 4 | View |
Latest News on ENTA